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Abstract
Background: The inclusion of cost-effectiveness data, as a basis for priority setting rankings, is a distinguishing feature 
in the formulation of the Swedish national guidelines. Guidelines are generated with the direct intent to influence 
health policy and support decisions about the efficient allocation of scarce healthcare resources. Certain medical 
conditions may be given higher priority rankings i.e. given more resources than others, depending on how serious the 
medical condition is. This study investigated how a decision-making group, the Priority Setting Group (PSG), used 
cost-effectiveness data in ranking priority setting decisions in the national guidelines for heart diseases. 
Methods: A qualitative case study methodology was used to explore the use of such data in ranking priority setting 
healthcare decisions. The study addressed availability of cost-effectiveness data, evidence understanding, interpretation 
difficulties, and the reliance on evidence. We were also interested in the explicit use of data in ranking decisions, 
especially in situations where economic arguments impacted the reasoning behind the decisions. 
Results: This study showed that cost-effectiveness data was an important and integrated part of the decision-making 
process. Involvement of a health economist and reliance on the data facilitated the use of cost-effectiveness data. 
Economic arguments were used both as a fine-tuning instrument and a counterweight for dichotomization. Cost-
effectiveness data were used when the overall evidence base was weak and the decision-makers had trouble making 
decisions due to lack of clinical evidence and in times of uncertainty. Cost-effectiveness data were also used for 
decisions on the introduction of new expensive medical technologies. 
Conclusion: Cost-effectiveness data matters in decision-making processes and the results of this study could be 
applicable to other jurisdictions where health economics is implemented in decision-making. This study contributes 
to knowledge on how cost-effectiveness data is used in actual decision-making, to ensure that the decisions are offered 
on equal terms and that patients receive medical care according their needs in order achieve maximum benefit.
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Implications for policy makers
• The inclusion of health economic aspects in the formulation of the Swedish national guidelines as a basis for priority setting rankings 
distinguishes them from the European counterparts. 
• Despite the increased use of cost-effectiveness data in decision-making, little is known about the actual use of such data in actual decision-
making.
• This study investigated how a decision-making group used cost-effectiveness data in ranking priority setting decisions in case of Swedish 
national guidelines for heart diseases, but the results could be applicable to other jurisdictions where health economics is implemented in 
decision-making.
• Cost-effectiveness data were used when the overall evidence base was weak and the decision-makers had trouble making decisions due to lack 
of clinical evidence and in times of uncertainty. 
• Cost-effectiveness data matters in decision-making processes and policy-makers could benefit from the results of this study.
Implications for public
The ultimate goal of national guidelines is to contribute towards patients receiving high quality medical care. Clinical guidelines are generated 
with the direct intent to influence health policy and support decisions about the efficient allocation of scarce healthcare resources. Thus, decision-
makers, policy-makers and politicians must give recommendations on how resources should be allocated. Certain medical conditions may be 
given higher priority rankings i.e. given more resources than others, depending on how serious the medical condition is. An important aspect of 
guidelines is that they should be based on current scientific research. Clinical scientific data, economic and ethical considerations influence the 
decision made. This study contributes to knowledge on how cost-effectiveness data is used in actual decision-making, to ensure that the decisions 
are offered on equal terms and that patients receive medical care according their needs in order achieve maximum benefit.
Key Messages 
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Introduction
The Swedish national guidelines use cost-effectiveness data 
as a basis for ranking decisions and Grip et al. reported that 
“health economics is an integrated part of the evidence base 
in the Swedish guidelines” (1). Cost-effectiveness data aid 
in the efficient management of scarce healthcare resources. 
Despite the increased production of cost-effectiveness data for 
decision-making, little is known about the actual use of such 
data. Empirical research has shown that Cost-Effectiveness 
Analysis (CEA), by themselves, have had limited impact on 
decision-makers (2,3). The low impact level of economic 
analyses on such decisions has raised concerns (4,5). 
Accessibility and acceptability barriers are often mentioned 
in the discussions of the limited impact or use of economic 
evaluation in decision-making (3). Having access to available 
evidence is important, though not sufficient, if the decision-
maker does not perceive cost-effectiveness evidence as 
acceptable. Scientific acceptability and institutional barriers 
have also been mentioned as a barrier in local decision-
making (2). In Sweden, empirical research has shown that 
healthcare decision-makers at the local level have not yet 
accepted the use of cost-effectiveness evidence in their 
decision-making to the same extent as at the national level 
concerning pharmaceuticals (6). 
This study aimed to investigate how a decision-making 
group used cost-effectiveness data in ranking priority 
setting decisions in case of Swedish national guidelines 
for heart diseases. The study addressed the availability of 
cost-effectiveness data, its understanding, interpretation 
difficulties, and the reliance on such evidence. We also 
investigated the explicit use of cost-effectiveness data in 
ranking decisions, especially situations where economic 
arguments impacted the reasoning behind the decisions. 
Setting 
The Swedish approach to priority setting is based on the ethics 
platform for making priority setting decisions in healthcare. 
These principles, in hierarchical order, are:
I. Human dignity principle: All individuals have equal value 
and rights regardless of their personal characteristics and 
social position.
II. Needs-solidarity principle: Healthcare resources should 
be allocated according to need.
III. Cost-effectiveness principle: Resources should be used in 
the most effective way without neglecting fundamental 
duties to improve health and quality of life (aimed at a 
reasonable relation between cost and effect) (7).
National model for priority setting 
Since the above ethical principles give little guidance on 
their application in explicit decision-making, a national 
model for transparent priority setting has been developed 
to operationalize the contents of the above principles 
(8). Since 2000, the Swedish National Board of Health 
and Welfare (NBHW) has used this model in producing 
treatment guidelines. The NBHW has facilitated knowledge 
management and has provided methodological support for 
the development of evidence-based treatment guidelines. 
Thus, according to Swedish law (9), care should be effective, 
evidence-based, patient focused, secure, and offered on 
equal terms.
The model includes several steps (Table 1) after the area for 
priority setting has been defined. The work process begins 
with “identifying the Prioritization Objects” (POs). The POs 
always consist of a medical condition-intervention pair. Both 
conditions and interventions must be present in a PO for 
the ethics platform to be fully implemented. Priority setting 
always means ranking something. The same intervention 
can be given different priorities depending on the medical 
conditions at which it is targeted. Step 1 represents the 
first box in Table 1. In order to create sufficient survey, the 
combinations of POs must be described in a uniform manner. 
According to the model, the POs should be clinically relevant 
rather than according to e.g. the specific design of a study. The 
aim of the PO is to give guidance in a specific decision situation 
in clinical practice. Thus, they could possibly be limited; 
focusing on typical cases in the daily routine, representing 
large volumes, and representing controversial areas where 
there are differences in praxis. They should also be based on 
decisions where the need for guidance for decision-makers 
is the greatest, e.g. expensive new treatments and in cases of 
uncertainty. Step 2 involves “reviewing and compiling current 
scientific knowledge and information”. Qualified experts are 
tied to the areas concerned. Subsequently, several medical 
expert groups as well as a health economic expert group 
were involved in reviewing and compiling current available 
scientific knowledge to produce decision support. The experts 
conduct systematic literature searches. The experts compile 
information on the severity of a condition, the patient benefit-
risk, and the cost-effectiveness. Step 3, which is the focus of 
this study, involves “producing a priority ranking decision”. 
This is achieved by weighing the evidence. Each PO is ranked, 
based on the reviewed and compiled scientific knowledge 
provided by the expert groups. A consensus process is used to 
rank each PO (10) (Figure 1).
Decision-making situation
The Priority Setting Group (PSG) consisted of 21 persons, 
which included medical professionals (e.g. cardiologist, 
thoracic surgeon, and clinical physiologist), clinical 
professionals (e.g. nurse, physiotherapist, and primary care 
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Figure 1. Priority setting decision-making at the national level.
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Table 1. Schematic description of the work process for the national guidelines
Medical condition
Intervention
Severity of the 
condition
Effect of 
intervention
Evidence of effect Cost per LY/ QALY 
gained
Health economic 
evidence
Ranking
1 2A 2B 3
1: Medical conditions and interventions are identified and paired, forming Prioritization Objects (POs). The pairs should be clinically relevant, 
possibly limited, focused on typical cases, and should represent large volumes and controversial areas with differences in medical praxis. 
The formal procedure consists of identifying current scientific knowledge through literature searches used as decision support. 
2A: Medical expert groups review and compile current scientific knowledge of the severity of the condition, effect on intervention and evidence 
of effect.
2B: The health economic expert group reviews and compiles current scientific knowledge of cost-effectiveness, integrated in the medical review. 
3: The Priority Setting Group (PSG) (decision-makers) produces a decision for each PO based on available evidence provided by the expert 
groups. The decisions are ranked on a scale from 1 to 10 for each medical condition and intervention.
Source: National guidelines for cardiac care 2008. Annex 3 to decision support documents – Method [modified] (10).
clinician), a health economist, and a medical ethicist.
The PSG ranked decisions for priority setting, based 
on the available clinical evidence in relation to costs 
provided by medical and health economic expert groups. 
Thus, development of treatment guidelines involved 
operationalization of the model’s contents into explicit 
ranking decisions. The model primarily aimed to guide policy 
decisions concerning patient groups at the national level.
Before each meeting, the members of the PSG, in pairs, 
had specific responsibility for reading up on the scientific 
evidence related to certain POs i.e. they had “homework 
assignments”. The work implied reviewing the evidence (the 
severity of the health condition, effect of treatment as well as 
its cost-effectiveness) provided by the expert groups. At each 
meeting, a preliminary proposal for ranking was presented 
(by the two PSG members with homework assignments), 
followed by a general discussion. A consensus process, i.e. 
justifying the proposal followed by open discussions, in order 
to reach a group ranking decision. Each PO was ranked on 
a scale ranging from 1 to 10, with 1 denoting the highest 
priority intervention and 10 denoting the lowest. The PSG 
members have responsibility for all POs. A consensus process 
is used during the entire work process.
The PSG started its work process in late 2006. By late 2007, 
their works were being circulated and openly discussed at 
regional seminars across the country prior to the publication 
of the final version.
Cost-effectiveness 
CEA always entails a choice between two or more comparable 
alternative treatment strategies. The results are often 
expressed in terms of cost per Quality-Adjusted Life-Year 
(QALY) gained. QALY combines quality of life with life years 
in relation to costs, and compares the value for money of 
alternative treatment strategies for a particular patient group. 
Lower costs for a more effective treatment strategy would 
imply that the intervention is considered to be dominant. 
However, decision-makers are often faced with interventions 
that are more effective but at an increased cost, i.e. they have 
to decide whether the society is willing to pay extra for a more 
effective treatment.
Available evidence on cost-effectiveness 
The evidence presented to the PSG on cost-effectiveness 
studies on heart disease treatments was based on systematic 
literature searches conducted by the health economic expert 
group (11,12). The overarching search term ‘Heart Diseases’ 
included several disease group areas and search terms within. 
The databases used to identify health economic analyses 
for the literature search were; NHS Economic Evaluation 
Database (NHS EED), Health Technology Assessment (HTA) 
Database, MEDLINE/PubMed and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL). 
The literature findings were presented in both short text 
descriptions and table formats for each PO, provided by the 
expert groups. The PSG either had access to this compiled 
information or cost-effectiveness data was lacking i.e. the 
work sheet was empty. Further, when cost-effectiveness data 
were lacking, simple model calculations were also conducted 
for certain POs where there was a need for guidance in clinical 
praxis were considered important and cost-effectiveness 
studies were lacking from the systematic literature searches 
e.g. catheter ablation treatment for atrial fibrillation. The 
worksheet included a box specifically for cost-effectiveness 
data and was, thus, an integral part of the evidence base 
(Table 1). As examples of use of cost-effectiveness data 
in the guidelines, we present the examples of implantable 
cardioverter defibrillators, catheter ablation treatment for 
atrial fibrillation and clopidogrel treatment in unstable 
angina. 
Methods
This study adopted a qualitative case study methodology, that 
used observations and semi-structured interviews as primary 
source data, and accessed all documentations provided to the 
PSG.
Data collection
Observations
Observation is the systematic watching and detailed 
recording of what people say and do. It often highlights 
discrepancies between data generated from documentary 
analyses, interview research, and observed behavior. 
Observations were conducted with the purpose of studying 
how the PSG used cost-effectiveness data in its decision-
making. Eleven full-day PSG meetings were held over the 
course of the work, of which three meetings were of two days. 
Field notes were taken during all the meetings. 
Eckard et al.
International Journal of Health Policy and Management, 2014, 3(6), 323–332326
Interviews
An interview is a communicative event with a purpose. It is 
a structured conversation with an attempt “to understand 
the world from the subject’s point of view” (13). A single 
investigator (NE) conducted all the face-to-face in-depth 
interviews of the PSG members. All the nine informants 
were approached after the PSG had completed its work, in 
order not to disturb the course of events during the work 
process. The sample represented geographic distribution, as 
well as all categories of specialty fields. The health economist 
was not included in the sample, as we were interested in 
how the decision-making group (non-economists), used 
available evidence that were not in their field of expertise. The 
interviews, were conducted using a semi-structured interview 
guide that addressed specific topics. All the interviews, which 
were between one to two hours, were recorded with assurances 
of confidentiality. 
Semi-structured interview research questions, enabled one 
to pursue other issues or concerns raised by the informant. 
Moreover, in-depth interviews allowed the researcher to 
ask follow-up questions and provided the informants an 
opportunity to expand on the themes they find important. All 
interviews began with introductory questions in which the 
informants were asked to briefly describe their background 
and explain how they first came in contact with the PSG. 
Specific open-ended questions were then asked to capture 
their description of the tasks and the use of cost-effectiveness 
data in decision-making, as well as any social context issues.
Data analysis
All the notes from the observations and interviews were 
transcribed the same day or the day after the meeting, followed 
by data analysis. Initial coding was conducted to identify 
different statements, i.e. either descriptive or thematic, and 
to look for recurrent topics, and patterns in the observations 
and interviews (14). Validity concerns whether the researcher 
is reflecting the phenomena being studied, as perceived by 
the study population. Both internal and external validity are 
strongly linked. To verify the internal validation of data, the 
data has been compared to other sections of data (constant 
comparative method) and checked for different perspectives 
are not ignored or forced upon. To verify external validation of 
data, triangulation of sources has been partly used, comparing 
interview data with data from observations. The primary 
research questions formed a structure for categorizing the 
research data. New themes and sub-themes were identified 
throughout data collection and analysis, which are illustrated 
as quoted comments from the informants. Early frameworks 
and concepts were treated as being tentative and were 
repeatedly refined as new and existing data were analyzed. 
Results
The findings include a systematic description and thematic 
analysis based on documents and observations of the 
meetings. The themes presented are accessibility (available 
cost-effectiveness data and level of understanding), 
acceptability (reliance and faith placed in the evidence) and 
use of cost-effectiveness data to form ranking decisions. 
The PSG’s task consisted of preparing ranking decisions, based 
on evidence-based knowledge, including cost-effectiveness, 
as part of the national model for priority setting. 
The PSG members became acclimatized to the work method 
at an initial “boot camp” with verbal explanations of the task 
and through practical exercises. The key notions of the PSG 
working model were explained and instructions were also 
given to allocate resources between different treatments. After 
an anonymous vote, the group went through the different 
proposals and openly discussed the reasoning behind their 
ranking decision. The members were allowed to ask questions, 
justify their proposals, and listen to why other members of the 
group had a high or low ranking. 
During the first meeting, the PSG received oral information 
from the project management on the basics of health 
economics, where cost-effectiveness was defined as “how 
much a society is willing to pay for a quality adjusted life year 
(QALY) and would imply that a medical intervention may be 
given a high priority even if the cost per QALY is considered 
high”. The members were asked to remember that a high cost 
per QALY may be given a high priority ranking and a low 
cost per QALY may be given a low priority ranking. They 
were informed that interventions “are allowed to cost money”, 
and that money used for one treatment strategy implies that 
another treatment strategy must give way. Reiteration strategy 
was used for reminding one another that all ranking decisions 
must be based on facts and evidence according to the national 
model. 
Accessibility
The PSG either had access to compiled information or 
cost-effectiveness data was lacking i.e. the work sheet was 
empty. The worksheet included a box specifically for cost-
effectiveness data and was, thus, an integral part of the 
evidence base (Table 1). Cost-effectiveness data was available 
for 57 of the 331 POs. When cost-effectiveness data was 
available, the POs could be based on several underlying 
studies for each PO. For 139 of the POs, a qualified estimation 
(low-moderate-high cost per QALY) was made, by the health 
economic experts after consultation with the medical experts. 
Often, cost-effectiveness studies were lacking, i.e. the boxes 
were empty for 135 of the POs. 
Available cost-effectiveness data to inform decisions 
The informants reported that cost-effectiveness data are 
crucial for ranking priority setting decisions. A specific box 
for cost-effectiveness data in the worksheet also reinforced the 
belief that economic evidence is important for the decision-
making process. One informant pointed out that the use of data 
in the decision-making process was something to be proud 
of - “we ‘dared’”. Others pointed out that it distinguished the 
guidelines from their European counterparts, as the following 
comments highlights:
“It is a strength that other countries do not have. […] In my 
experience, they are lagging [in Europe]”.
The observations showed that PSG members were exposed to 
a lot of information before each meeting. The sheer number 
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of POs in the guideline document was more than 300. The 
members were consistently reminded, by the chairperson and 
the members of the steering committee, to include economic 
aspects while ranking the decisions. 
Level of understanding
Several informants identified that they had limited access to 
in-depth written materials and also a limited understanding 
of health economics. One informant commented:
“I don’t believe very many people have read this [the health 
economic facts document], and there is a widespread 
ignorance about it. So, there are short-comings in our 
understanding”.
The informants were concerned about the lack of cost-
effectiveness data, and found it difficult to always make use of 
cost-effectiveness arguments in the decision-making process. 
A few informants questioned the results of model-based 
approaches and mentioned their limited understanding of 
the underlying assumptions in cost-effectiveness studies – for 
example:
“Now and then there were studies, but many boxes were 
empty. The health economic evidence base was a more or less 
weak foundation the whole time”.
Acceptability
Reliance on the available evidence
The informants identified that there is an acceptance of 
and interest in health economics, specifically within the 
cardiovascular field, as the following comments suggest: 
“There is a self confidence in heartcare. We know that we 
give ‘value for money’”.
“Cardiologists have a higher awareness of health economics 
than do others in the medical profession”.
The informants also perceived the health economist, who 
was present during the entire process, to be a credible 
representative of the health economic academic community. 
“[Cost-effectiveness data] is built on a scientific foundation, 
and I have them utmost respect for the [health economic] 
field”.
“I have the utmost respect for the fact that this is a 
knowledgeable person from the world of research making an 
educated guess”.
A recurrent theme that the informants brought up was 
their reliance on a health economist during all meetings, as 
expressed by the following comment:
“When you are ignorant and don’t understand something, 
you tend to disregard it and take some easy interpretations. 
So I think the fact that they have put a health economist in 
place here means a lot”.
A concern relating to poor levels of understanding was that 
too much faith might be placed on the use of cost-effectiveness 
data. An informant expressed that health economic evidence 
“becomes a ‘truth’” and another informant said that the cost-
effectiveness evidence was never questioned when available. 
Other informant comments connected to this theme are as 
follows:
“I believe that owing to general ignorance, when you don’t 
understand something, you sometimes trust the written 
word and such, and there is this tendency, of course, because 
several big names [senior authorities] think this
[Health Economics] is an acceptable science”.
An interesting finding was that other informants conveyed 
that their faith increased when the health economist identified 
and expressed the lack of evidence. Many informants realized 
that an evidence-based approach does not always signal the 
presence of Randomized Controlled Trials. It also involves 
accounting for the lack of evidence, indicating a limited 
evidence base, as the following quoted comments suggest:
“I appreciated the fact that [the health economist] also said 
there was no evidence. Evidence-based medicine is not 
about only finding the best studies with the highest grade 
of evidence, but also about expressing the lack of evidence. 
Indicating a lack of evidence and making an educated guess 
wins respect”.
Another theme expressed by the informants was the use of 
cost-effectiveness data perceived as a means of obtaining 
healthcare resources such as new expensive medical 
technologies. One particular informant indicated that cost-
effectiveness data were not perceived as a threat but rather as 
a useful decision tool. An example of this theme is catheter 
ablation treatment which is illustrated later in this paper. 
Balancing available evidence
The informants generalized that cost-effectiveness data 
were important in reaching a decision and that they do not 
primarily consider economic arguments. Most of them 
focused on the clinical effectiveness side because of their 
own area of expertise. They also expressed that they focused 
more on clinical effectiveness and the patient’s needs. Cost-
effectiveness was not reviewed and challenged to the same 
extent as clinical evidence, as indicated in the following 
comments:
“Now and then, it came up, but not at all in the same manner 
as for those who had written the medical facts”.
“You have to be a little pragmatic here. It [using cost-
effectiveness data] is so new still so new…if they’d taken a 
completely different approach and for each case and looked 
at the underlying studies, as they did here [evidence of effect], 
they would have wound up speaking to deaf ears… So it’s, 
you know… it is a balancing act”.
Thus, cost-effectiveness data were seen as a supplement to 
clinical evidence. Primarily, the informants considered both 
clinical effectiveness of the treatment and the associated risks 
when reaching a decision and secondly, cost-effectiveness 
data. 
Use of cost-effectiveness data to form ranking decisions
Dichotomization 
Particular emphasis was placed on examining evidence 
that supports the PSG’s ranking decisions and helps reach 
consensus decisions. When asked to reflect on situations 
when economic arguments were used in the decisions, a 
majority of informants had difficulty in isolating the cost-
effectiveness data from the collected evidence base. Many 
pointed out that they had doubts about using the evidence 
base when it was weak, although they had to take a position 
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in order to reach consensus. 
The findings suggest that the PSG found it difficult to spread 
the ranking decisions evenly on the 10-grade scale. The group 
tends to award either a high or a low ranking, which resulted in 
a U-shaped curve, i.e. a majority of ranking decisions entailed 
either high or low rankings and were adapted to become a 
Yes or No answer. Of the 300 POs only 31 were ranked 5 or 
6. Thus, dichotomizing the POs in terms of favoring (high 
rankings, 1 to 4) the medical condition and intervention or 
disfavoring (low rankings, 7 to 10) the treatments, was used 
as a solution in reaching consensus on the ranking decisions. 
The PSG found it difficult to reach a consensus in case of 
no evidence of clinical efficacy, and overall weak evidence 
base. The discussions were characterized by the need for new 
POs. Creating new POs was sometimes used as a strategy to 
advance the work forward, often resulting in dichotomization.
Adjustment of ranking decisions 
Even if the informants had difficulty in giving examples of 
the specific use of cost-effectiveness data, the observations 
show that economic arguments were used after a preliminary 
ranking decision had been made that favored or disfavored 
the treatment. A ranking between 1 and 3 signaled that the 
PO will be carried out in medical praxis, a ranking of 4 to 6 
signaled that it ought to be carried out, and a ranking of 7 to 
10 signaled that it might be carried out. A ranking of 10 was 
indicated that a PO was used as an exception in medical praxis 
and only in cases of affordability. Thus, economic arguments 
were used in the group’s deliberations after dichotomization 
to adjust the ranking decisions.
The availability of cost-effectiveness data did not always 
conclude that high cost-effectiveness ratios would imply low-
ranking decisions. Certain POs were given high rankings 
even though the cost per QALY was judged to be high. The 
PSG members interpreted that the society is willing to pay 
more for severe diseases - i.e. when need was considered, 
thereby, influencing the ranking decisions. The findings from 
the observations indicate that it was easier to reach consensus 
on ranking decisions for high rankings, even when cost-
effectiveness data on such strategies as life-saving intervention 
were lacking.
Examples of situations of the use of cost-effectiveness data 
The following examples have been chosen to highlight cases 
when the PSG made use of cost-effectiveness data in their 
decision-making. 
Implantable cardioverter defibrillators
Cost-effectiveness data that were available for both secondary 
and primary preventive use of ICDs varied, depending 
on the risk for sudden death, from a moderate (100,000 ≤ 
500,000 SEK) to a high (500,000 ≤ 1,000,000 SEK) cost per 
QALY gained compared with the cost-effectiveness data 
for antiarrhythmic medical treatment. The higher the risk 
for sudden death, the lower the cost per QALY gained. The 
secondary preventive use of ICDs was given a ranking of 2 
and the primary preventive use was given a ranking of 4. 
Economic arguments were used during the group’s 
deliberations focusing on the implication on budget impact 
of a high priority ranking decision. Arguments were based 
on the survival benefit for the patient population as a whole, 
including quality-of-life measures. The survival benefits were 
weighted against the increased cost of the device. Initially, the 
PSG made a decision in favor of the treatment and thereafter 
cost-effectiveness data was included in the discussion. The 
implications of the implementation of an expensive medical 
technology, such as ICD, was discussed. Although implantable 
ICDs are potentially life-saving devices for people at risk of 
sudden death as a result of cardiac arrhythmias, it was not 
given the highest ranking of 1 (Table 2). 
Catheter ablation treatment 
The PSG faced difficulty in reaching a ranking decision 
in the case of catheter ablation used for the treatment of 
patients suffering from symptomatic atrial fibrillation. Cost-
effectiveness data, in the form of a simple model calculation, 
had been provided by the health economic expert group 
for the group’s deliberations. Thus, the steering committee 
identified a need for cost-effectiveness evidence, as a basis for 
the PSGs decision-making. The deliberations were adjourned 
several times in the course of the work, and significant time 
was spent considering the signal value of the decision. The 
group was concerned about the long-term efficacy of the 
treatment and a lack of cost-effectiveness data.
Despite its higher initial intervention costs, catheter ablation 
treatment was considered a cost-effective intervention 
compared with medical management and was estimated at a 
low (≤100,000 SEK) cost per QALY gained for patients who 
previously failed to respond to medical management. The PO 
was finally given a ranking of 4. The PSG’s decision, reflects 
that new cost-effectiveness data have become available, 
justifying a ranking decision in favor of the treatment. 
Thus, the treatment ought to be considered as an alternative 
for patients who have not responded to previous medical 
management (Table 3). 
Clopidogrel plus Acetylsalicylic Acid (aspirin) 
Clopidogrel is used with Acetylsalicylic Acid (ASA) for the 
treatment of unstable angina as a secondary prevention of 
Percutaneous Coronary Intervention (PCI) for three to 12 
months. Cost-effectiveness ratios were estimated at a low 
(≤100,000 SEK) to moderate (100,000 ≤ 500,000 SEK) cost 
per QALY gained for the combination of clopidogrel and 
aspirin versus aspirin alone. 
During the group’s deliberations, the members’ arguments 
primarily concerned the medical evidence, i.e. avoidance of 
ischemic events weighted against the excess risk of bleeding. 
The PO was finally given a high priority of 3, reflecting the 
low cost-effectiveness ratios and the evidence which were 
available for the intervention (Table 4). (The high ranking 
decision may be viewed against the previous edition of the 
guidelines when clopidogrel was given a low ranking decision 
reflecting sparse cost-effectiveness evidence then available).
Implications for healthcare organizations
The PSG’s ranking decisions have implications for the 
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Table 2. Examples of priority setting ranking decisions for ICD
Medical condition
Intervention
Severity of the 
condition
Effect of intervention Evidence of 
effect
Cost per LY/ 
QALY gained
Health 
economic 
evidence
Ranking**
Risk of sudden death for patients 
with ischemic heart disease, 
impaired Ejection Fraction (EF 
≤35%) and function class NYHA II-III 
at least 3 months after MI, in spite 
of optimal medical management for 
heart failure
ICD
(primary prophylaxis)
High risk of 
premature death.
Low to high need 
of symptom relief. 
Low to major 
impact on quality 
of life.
Moderate to high 
reduction of risk for 
premature death. 
No to low effect on 
symptoms. Positive 
to negative effect on 
quality of life. Low 
to moderate risk for 
pre- and post-operative 
complications. 
Evidence level 
1 for reduction 
of risk for 
premature 
death
ICD vs. 
conventional 
medical 
management 
Moderate to 
high*
Good 
scientific 
evidence
4
Ventricular arrhythmia (VT/VF) 
with cardiac arrest or syncope for 
patients with/without impaired left 
ventricular function
ICD
(secondary prophylaxis)
High risk of 
premature death.
High need of 
symptom relief.
Major impact on 
quality of life.
Moderate to high 
reduction of risk for 
premature death. 
Low to high reduction 
on symptoms. No to 
high improvement 
on quality of life. Low 
to moderate risk for 
pre- and post-operative 
complications.
Evidence level 
1 for reduction 
of risk for 
premature 
death 
compared 
to medical 
management 
ICD vs. 
conventional 
medical 
management
Moderate to 
high*
Good 
scientific 
evidence
2
ICD= Implantable Cardioverter Defibrillator; LY= Life-Year; MI= Myocardial Infarction; NYHA= New York Heart Association; QALY= Quality-Adjust-
ed Life-Year; VF= Ventricular Fibrillation; VT= Ventricular Tachycardia.
*Low [≤100,000 SEK (11,000 Euro)]; Moderate [100,000 ≤ 500,000 SEK (11,000 ≤ 55,000 Euro)]; High [500,000 ≤ 1,000,000 SEK (55,000 ≤ 
111,000 Euro)]; Very high [>1,000,000 SEK (111,000 Euro)] cost per QALY gained.
**1 denotes an intervention with the highest priority ranking and 10 with the lowest.
Source: National guidelines for cardiac care 2008. Table annex to decision support document – Medical conditions and interventions for heart 
diseases [translated] (15).
Table 3. Example of a priority setting ranking decision for catheter ablation
Medical condition
Intervention
Severity of the 
condition
Effect of intervention Evidence of 
effect
Cost per LY/ 
QALY gained
Health 
economic 
evidence
Ranking**
Symptomatic or persistent 
atrial fibrillation in spite of 
adequate antiarrhythmic 
medical management
Catheter Ablation
Low to moderate 
risk of premature 
death. 
High need for 
symptom relief.
Major impact on 
quality of life.
Favorable effect on symptomatic 
atrial fibrillation (56%–86%). 
1%-6% serious complication 
risk, including low mortality 
risk. Unknown effect on risk of 
premature death. 
Good scientific 
evidence
Catheter 
ablation vs. 
antiarrhythmic 
drug treatment
Low*
Good 
scientific 
evidence
4
LY= Life-Year; QALY, Quality-Adjusted Life-Year.
*Low [≤ 100,000 SEK (11,000 Euro)]; Moderate [100,000 ≤ 500,000 SEK (11,000 ≤ 55,000 Euro)]; High [500,000 ≤ 1,000,000 SEK (55,000 ≤ 
111,000 Euro)]; Very high [>1,000,000 SEK (111,000 Euro)] cost per QALY gained.
**1 denotes an intervention with the highest priority ranking and 10 with the lowest.
Source: National guidelines for cardiac care 2008. Table annex to decision support document – Medical conditions and interventions for heart 
diseases [translated] (15).
guidance of clinical decisions on a group level, as well as 
for resource allocation within cardiac care. We have already 
shown that economic arguments, such as implications for 
budget impact, were used during the group’s deliberations 
in the case of ICDs. Another example of using economic 
arguments, was the case of warfarin (anticoagulation 
treatment) used for heart disease patients in the prevention 
of stroke. In the group discussion, the PSG recognized that 
preventive treatment in heart disease patients could have 
implications for the healthcare system as a whole and also 
reduce the costs to society by avoiding the costs related 
to stroke care. The informants mentioned that a societal 
perspective was included in the reasoning behind the ranking 
decisions, as highlighted by one informant:
“Considering - the healthcare system as a whole, rather than, 
a particular clinic”.
The concept of the National Model for Transparent 
Prioritization in Swedish Health Care was not familiar to all 
the PSG members prior to their work. Producing priority 
ranking decisions by weighing evidence and including cost-
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effectiveness data was perceived as a new way of thinking. One 
informant concluded in their interview that “affordability” is 
often a pressing issue at the local level of decision-making and 
in that sense associated as “something negative” and continued 
“but that is not what I associate with the term ‘health economics’ 
now”. Instead, ethical considerations were emphasized as well 
as general discussions on what was considered “reasonable” 
investments. 
Discussion
This study reports the findings of a case study on the national 
guidelines for heart diseases in Sweden (16). It uses qualitative 
methodology to explore various themes on the use of cost-
effectiveness data in priority setting ranking decisions. It 
addresses themes related to the availability of cost-
effectiveness data, understanding of the data, interpretation 
difficulties, and the reliance on the evidence. 
Cost-effectiveness data were accessed in condensed text form 
and verbally through the health economist present at the 
PSG’s meetings. The involvement of a health economist as a 
member of PSG and the steering committee reinforced the 
notion that health economics is important throughout the 
group’s work. 
This study supports the fact that healthcare decision-makers 
at the national level have accepted the use of cost-effectiveness 
in their decision-making process. We have given examples of 
situations where economic arguments were used in explicit 
decision-making. The group reasoned using economic 
considerations when the overall evidence base was weak and 
they had trouble taking decisions. 
One problem mentioned was the lack of evidence, which 
implicated the faith placed in the evidence. Previous research 
has shown that even if economic arguments are significant, 
the expected benefits and risks of a treatment are the most 
important factors in making priority setting decisions (17). 
Others have reported several important reasons for drug 
priority setting and no single dominated in reaching a 
decision-making (18). Our findings also verify the notion that 
cost-effectiveness data are not challenged to the same extent 
as clinical evidence and that greater weight is given to the 
clinical effectiveness side. 
A similar methodology was used in a UK study where cost-
effectiveness was used to structure the discussions and 
manage the complexity in the decision problem (19). The 
UK study included health economic experts as informants, 
thus, indicating that economic arguments were an important 
facilitating factor in the process. Moreover, the informants in 
the UK study had a more critical view and in-depth level of 
knowledge compared to our study. In our study, more than 
300 POs were assessed compared to seven included in the UK 
study. Thus, less time was spent per appraisal topic. However, 
the findings of both the studies were largely similar.
The categories, accessibility and acceptability barriers are 
often mentioned in the discussions of the limited impact or 
use of economic evaluation in decision-making (3). Several 
studies have highlighted the difficulties decision-makers 
face in obtaining economic evaluations due to shortage of 
relevant analyses or problems accessing those published 
(2). Decision-makers often struggle with understanding 
health economic analyses given the concepts, language 
and presentation style. Acceptability barriers refer to all 
barriers that arise after economic evaluations have been 
accessed and understood, such as; scientific acceptability and 
institutional barriers (especially mentioned as a barrier in 
local decision-making) (2,6). 
Affordability is often a pressing issue at local level decision-
making. Outcomes are seldom viewed in relation to cost, 
i.e. clinicians are often concerned with clinical effectiveness. 
Managers are often focused on reducing costs i.e. length of 
stay in hospital or expensive equipment. Neither view relates 
to both costs and effect. Thus, local level decision-makers 
often have no incentive to promote the status of economic 
evaluations as there is no framework to incorporate cost-
effectiveness data. Empirical research has shown that 
healthcare decision-makers at the local level have not yet 
accepted cost-effectiveness data to the same extent as at the 
national level. 
This study, sheds light on a framework to incorporate cost-
effectiveness data in national level policy decision-making. 
Though, the decisions made by the PSG, are based on the 
severity of the disease and clinical effectiveness as well as cost-
effectiveness data. Economic evidence should be viewed as 
Table 4. Example of priority setting ranking decision for Clopidogrel
Medical condition
Intervention
Severity of 
the condition
Effect of intervention Evidence of 
effect
Cost per LY/ 
QALY gained
Health 
economic 
evidence
Ranking**
Unstable coronary 
artery disease
Clopidogrel plus 
ASA, 3 to 12 
months
Moderate risk 
of premature 
death
ASA + clopidogrel, compared to ASA, reduced (non-
fatal MI, stroke or cardiovascular death), from 11.4 
to 9.3 (RR= 0.80, CI= 0.72–0.90). 
No significant difference in cardiovascular death 
separately. Increase in major bleeds from 2.7 to 3.7 
% (RR= 1.38, CI= 1.13–1.67). 
Good 
scientific 
evidence
Clopidogrel 
vs. standard 
treatment 
(ASA)
Low to 
moderate*
Good 
scientific 
evidence
3
ASA= Acetylsalicylic Acid; CI= Confidence Interval; LY= Life-Year; QALY= Quality-Adjusted life-Year; RR=  Relative Risk.
*Low [≤ 100,000 SEK (11,000 Euro)]; Moderate [100,000 ≤ 500,000 SEK (11,000 ≤ 55,000 Euro)]; High [500,000 ≤ 1,000,000 SEK (55,000 ≤ 
111,000 Euro)]; Very high [>1,000,000 SEK (111,000 Euro)] cost per QALY gained.
**1 denotes an intervention with the highest priority ranking and 10 with the lowest.
Source: National guidelines for cardiac care 2008. Table annex to decision support document – Medical conditions and interventions for heart 
diseases [translated] (15).
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part of the evidence-based knowledge “package”. It is not our 
intent to argue that healthcare priority setting should be based 
solely on cost-effectiveness data. The use of cost-effectiveness 
data represented one of many factors that play a part in 
health policy decision-making. A consideration is that most 
informants had difficulty isolating cost-effectiveness evidence, 
which represented a sub-component of the accumulated 
evidence base taken into account in decision-making.
There are several models to explain research utilization. In 
a knowledge-driven model, presenting and communicating 
policy-makers with research, is sufficient to ensure research 
use. Other models focus on research being compatible with 
the goals and needs of the decision-makers. An interactive 
model, on the other hand, implies a non-linear process of 
interconnections in order to make sense of the problem 
and research is seen as one part in a complicated process to 
reach decisions. Decision-making may also be viewed as a 
constellation of interests and pressures or tactical models to 
avoid responsibility for unpopular policy outcomes (20). 
In Sweden, the ethics platform establishes the principles for 
priority setting in healthcare. The values underlying the ethics 
platform are that priorities are based on generally accepted 
principles, e.g. that the rankings must be perceived to be fair 
by most of the population to maintain confidence and the 
will to publically finance healthcare – a condition, that the 
government believes will facilitate understanding of the need 
to set priorities in healthcare. From an institutional design 
perspective, the delegation of institutional powers may be 
viewed as one among several tactics for politicians seeking 
to remove the challenge of setting limits to public services 
from the political agenda (21,22). The delegators often 
enjoy a considerable degree of discretion. The work national 
guidelines for heart diseases is funded by the NBHW, who are 
commissioned by the Government and the Ministry of Social 
Affairs to coordinate the work. The decisions made by the 
PSG are not immediately binding and the decisions constitute 
recommendations. The NBHW also draws up a number of 
indicators of good standard of care and have implications for 
health services which are central for decision-makers. 
The barriers of use may also be associated with institutional 
considerations such as; stated aims and goals, relationship to 
implementation, institutional affiliation of actors and external 
scrutiny levels (23). This study showed that the goals were 
clearly stated and there was a framework to organize the cost-
effectiveness data. This would increase the PSG’s incentive to 
use the data in their decision-making. The fact that the PSG 
were struggling to understand presented evidence may have 
decreased the incentives to use the data. The relationship 
to implementation was indirect, as the decisions were not 
immediately binding and on the national level, and would 
increase the incentives of use. The affiliations of the actors 
in the PSG may help to explain the predominant clinical-
effectiveness used by the PSG members. The awareness of 
external scrutiny would also increase the incentives to use. 
If the guidelines are to be implemented and be perceived as 
legitimate and fair, it is important for all the PSG members to 
stand by all the decisions made by the group.
Using both observations and in-depth interview as a 
research methodology, is a strength in our study design. 
The participation in all PSG group meetings gave insight 
to the entire work process. The interviews supplemented 
the findings from the observations, giving a richness to the 
themes generated. However, our paper has limitations. Not all 
members of the PSG were interviewed. The sample sought to 
achieve broad representation. A limitation in our study may 
have been that the informants were clinicians working in a 
specialist unit and in the cardiovascular field and had a high 
awareness and wide-spread acceptance of the use of including 
cost-effectiveness data in ranking decisions. As with all 
qualitative research methodology, a concern was whether our 
findings are context specific or not. We believe that further 
research is needed on the inclusion of cost-effectiveness data 
in policy guidelines for other disease areas.
Conclusion
Cost-effectiveness data were concluded to be an important 
and integrated part of the decision-making process on the 
Swedish national guidelines for heart diseases. Involvement of 
a health economist and reliance on the data facilitated the use 
of data in the decision-making process. Economic arguments 
were a fine-tuning instrument and a counterweight for 
dichotomization. Cost-effectiveness data were used when 
the overall evidence base was weak and the PSG had trouble 
making decisions. Cost-effectiveness data were also used 
for decisions on the introduction of new expensive medical 
technologies. 
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